RUBY insider filings
Rubius Therapeutics, Inc. — 39 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-02-27. Screen RUBY transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for RUBY between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Rubius Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-02-27 | 4 | Appelhans Dannielle — CEO and President | Sale (S): 10,385 @ $0.13 | EDGAR |
| 2023-02-01 | 4 | Appelhans Dannielle — CEO and President | Option exercise (M): 7,500 · Sale (S): 3,878 @ $0.25 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | CAGNONI PABLO J — Director | Sale (S): 8,448 @ $0.25 | EDGAR |
| 2023-01-31 | 4 | Turka Laurence A. — Chief Scientific Officer | Option exercise (M): 7,438 · Option exercise (M): 8,625 · Sale (S): 2,593 @ $0.24 · Option exercise (M): 7,438 (derivative) @ $0 · Option exercise (M): 8,625 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | CAGNONI PABLO J — Director | Option exercise (M): 21,250 · Option exercise (M): 25,000 · Sale (S): 7,240 @ $0.24 · Option exercise (M): 21,250 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2022-08-12 | 4 | Appelhans Dannielle — Chief Operating Officer | Option exercise (M): 12,500 · Sale (S): 5,737 @ $0.80 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Schaffert Susanne — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Prener Anne — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Symonds Jonathan — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Holles Natalie C. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Sohn Catherine A. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Cuss Francis M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Rosenblatt Michael — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | Epstein David R — Director | Grant/award (A): 499,762 (derivative) @ $0 | EDGAR |
| 2022-05-13 | 4 | AFEYAN NOUBAR — Director, 10% owner | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-04-22 | 4 | Epstein David R — Director | Purchase (P): 30,000 @ $1.44 | EDGAR |
| 2022-02-01 | 4 | Appelhans Dannielle — Chief Operating Officer | Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | Turka Laurence A. — Chief Scientific Officer | Option exercise (M): 7,438 · Sale (S): 2,517 @ $6.57 · Option exercise (M): 7,438 (derivative) @ $0 · Grant/award (A): 143,750 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | Carmona Jose — Chief Financial Officer | Grant/award (A): 143,750 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | Keson-Brookes Maiken — CLO & Corp. Secretary | Option exercise (M): 8,075 · Sale (S): 2,732 @ $6.57 · Option exercise (M): 8,075 (derivative) @ $0 · Grant/award (A): 143,750 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0 | EDGAR |
| 2022-02-01 | 4 | CAGNONI PABLO J — CEO and President, Director | Option exercise (M): 21,250 · Sale (S): 6,730 @ $6.57 · Option exercise (M): 21,250 (derivative) @ $0 · Grant/award (A): 365,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-09-01 | 4 | Appelhans Dannielle — Chief Operating Officer | Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Prener Anne — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Symonds Jonathan — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Holles Natalie C. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Sohn Catherine A. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Cuss Francis M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Rosenblatt Michael — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | Epstein David R — Director | Grant/award (A): 27,919 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | AFEYAN NOUBAR — Director, 10% owner | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-03-23 | 4 | Flagship Ventures Fund IV General Partner LLC — 10% owner Flagship Ventures Fund IV, L.P. — 10% owner Flagship Ventures Fund V General Partner LLC — 10% owner Flagship Ventures Fund V, L.P. — 10% owner Flagship Ventures Opportunities Fund I General Partner LLC — 10% owner Flagship Ventures Opportunities Fund I, L.P. — 10% owner AFEYAN NOUBAR — Director, 10% owner | Purchase (P): 70,000 @ $29 · Purchase (P): 70,000 @ $29 · Purchase (P): 70,000 @ $29 | EDGAR |
| 2021-03-15 | 4 | Keson-Brookes Maiken — CLO & Corp. Secretary | Option exercise (M): 25,000 @ $7.70 · Sale (S): 25,000 @ $20.24 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2021-02-16 | 4 | Epstein David R — Director | Sale (S): 26,704 @ $14.93 | EDGAR |
| 2021-02-10 | 4 | Epstein David R — Director | Sale (S): 89,233 @ $14.88 · Sale (S): 2,100 @ $14.83 · Sale (S): 7,404 @ $14.79 | EDGAR |
| 2021-02-02 | 4 | Coughlin Christina M. — Chief Medical Officer | Grant/award (A): 142,500 (derivative) @ $0 · Grant/award (A): 32,300 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Turka Laurence A. — Chief Scientific Officer | Grant/award (A): 131,250 (derivative) @ $0 · Grant/award (A): 29,750 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Keson-Brookes Maiken — CLO & Corp. Secretary | Grant/award (A): 142,500 (derivative) @ $0 · Grant/award (A): 32,300 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | CAGNONI PABLO J — CEO and President, Director | Grant/award (A): 375,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2020-12-02 | 4 | Carmona Jose — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Rubius Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-04-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-03 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-02-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-06 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-12-21 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2022-12-14 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-02 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-10-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-10-13 | 8-K | 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RUBY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs